258 related articles for article (PubMed ID: 22458939)
1. A randomised, placebo-controlled, dose-finding study of AZD9668, an oral inhibitor of neutrophil elastase, in patients with chronic obstructive pulmonary disease treated with tiotropium.
Vogelmeier C; Aquino TO; O'Brien CD; Perrett J; Gunawardena KA
COPD; 2012 Apr; 9(2):111-20. PubMed ID: 22458939
[TBL] [Abstract][Full Text] [Related]
2. AZD9668, a neutrophil elastase inhibitor, plus ongoing budesonide/formoterol in patients with COPD.
Kuna P; Jenkins M; O'Brien CD; Fahy WA
Respir Med; 2012 Apr; 106(4):531-9. PubMed ID: 22197578
[TBL] [Abstract][Full Text] [Related]
3. Phase II study of a neutrophil elastase inhibitor (AZD9668) in patients with bronchiectasis.
Stockley R; De Soyza A; Gunawardena K; Perrett J; Forsman-Semb K; Entwistle N; Snell N
Respir Med; 2013 Apr; 107(4):524-33. PubMed ID: 23433769
[TBL] [Abstract][Full Text] [Related]
4. A 4-year trial of tiotropium in chronic obstructive pulmonary disease.
Tashkin DP; Celli B; Senn S; Burkhart D; Kesten S; Menjoge S; Decramer M;
N Engl J Med; 2008 Oct; 359(15):1543-54. PubMed ID: 18836213
[TBL] [Abstract][Full Text] [Related]
5. Effect of once-daily fluticasone furoate/vilanterol on 24-hour pulmonary function in patients with chronic obstructive pulmonary disease: a randomized, three-way, incomplete block, crossover study.
Boscia JA; Pudi KK; Zvarich MT; Sanford L; Siederer SK; Crim C
Clin Ther; 2012 Aug; 34(8):1655-66.e5. PubMed ID: 22789766
[TBL] [Abstract][Full Text] [Related]
6. Tiotropium as a first maintenance drug in COPD: secondary analysis of the UPLIFT trial.
Troosters T; Celli B; Lystig T; Kesten S; Mehra S; Tashkin DP; Decramer M;
Eur Respir J; 2010 Jul; 36(1):65-73. PubMed ID: 20185426
[TBL] [Abstract][Full Text] [Related]
7. Safety and efficacy of the once-daily anticholinergic BEA2180 compared with tiotropium in patients with COPD.
Abrahams R; Moroni-Zentgraf P; Ramsdell J; Schmidt H; Joseph E; Karpel J
Respir Med; 2013 Jun; 107(6):854-62. PubMed ID: 23490224
[TBL] [Abstract][Full Text] [Related]
8. COPD in young patients: a pre-specified analysis of the four-year trial of tiotropium (UPLIFT).
Morice AH; Celli B; Kesten S; Lystig T; Tashkin D; Decramer M
Respir Med; 2010 Nov; 104(11):1659-67. PubMed ID: 20724131
[TBL] [Abstract][Full Text] [Related]
9. Feasibility of Computed Tomography in a Multicenter COPD Trial: A Study of the Effect of AZD9668 on Structural Airway Changes.
Nordenmark LH; Taylor R; Jorup C
Adv Ther; 2015 Jun; 32(6):548-66. PubMed ID: 26043724
[TBL] [Abstract][Full Text] [Related]
10. Tiotropium administered by a pressurized metered dose inhaler (pMDI) and spacer produces a similar bronchodilator response as that administered by a Rotahaler in adult subjects with stable moderate-to-severe COPD.
Brashier B; Dhembare P; Jantikar A; Mahadik P; Gokhale P; Gogtay JA; Salvi SS
Respir Med; 2007 Dec; 101(12):2464-71. PubMed ID: 17719763
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of tiotropium in COPD patients from Asia: a subgroup analysis from the UPLIFT trial.
Fukuchi Y; Fernandez L; Kuo HP; Mahayiddin A; Celli B; Decramer M; Kesten S; Liu D; Tashkin D
Respirology; 2011 Jul; 16(5):825-35. PubMed ID: 21539680
[TBL] [Abstract][Full Text] [Related]
12. The efficacy of tiotropium administered via Respimat Soft Mist Inhaler or HandiHaler in COPD patients.
van Noord JA; Cornelissen PJ; Aumann JL; Platz J; Mueller A; Fogarty C
Respir Med; 2009 Jan; 103(1):22-9. PubMed ID: 19022642
[TBL] [Abstract][Full Text] [Related]
13. Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trial.
Decramer M; Celli B; Kesten S; Lystig T; Mehra S; Tashkin DP;
Lancet; 2009 Oct; 374(9696):1171-8. PubMed ID: 19716598
[TBL] [Abstract][Full Text] [Related]
14. [A randomized, double-blind, placebo-control study of once-daily inhaled tiotropium in chronic obstructive pulmonary disease].
Yin KS; Zhang DP; Shi Y; Sun LH; Min R; Xiao YL; Xia XR; Tan Y; Fu WZ
Zhonghua Jie He He Hu Xi Za Zhi; 2010 Jul; 33(7):519-23. PubMed ID: 20979799
[TBL] [Abstract][Full Text] [Related]
15. Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials.
Fabbri LM; Calverley PM; Izquierdo-Alonso JL; Bundschuh DS; Brose M; Martinez FJ; Rabe KF;
Lancet; 2009 Aug; 374(9691):695-703. PubMed ID: 19716961
[TBL] [Abstract][Full Text] [Related]
16. Impact of tiotropium on the course of moderate-to-very severe chronic obstructive pulmonary disease: the UPLIFT trial.
Tashkin DP
Expert Rev Respir Med; 2010 Jun; 4(3):279-89. PubMed ID: 20524910
[TBL] [Abstract][Full Text] [Related]
17. Tiotropium in COPD patients not previously receiving maintenance respiratory medications.
Adams SG; Anzueto A; Briggs DD; Menjoge SS; Kesten S
Respir Med; 2006 Sep; 100(9):1495-503. PubMed ID: 16698259
[TBL] [Abstract][Full Text] [Related]
18. Efficacy, safety and effect on biomarkers of AZD9668 in cystic fibrosis.
Elborn JS; Perrett J; Forsman-Semb K; Marks-Konczalik J; Gunawardena K; Entwistle N
Eur Respir J; 2012 Oct; 40(4):969-76. PubMed ID: 22267768
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of the efficacy and safety of tiotropium bromide (5 µg) inhaled via Respimat in Chinese patients with chronic obstructive pulmonary disease.
Tang Y; Massey D; Zhong NS
Chin Med J (Engl); 2013; 126(19):3603-7. PubMed ID: 24112149
[TBL] [Abstract][Full Text] [Related]
20. Acute effects of indacaterol on lung hyperinflation in moderate COPD: a comparison with tiotropium.
Rossi A; Centanni S; Cerveri I; Gulotta C; Foresi A; Cazzola M; Brusasco V
Respir Med; 2012 Jan; 106(1):84-90. PubMed ID: 22035851
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
